Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter January 30, 2019

One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty

  • Andrea J. Arcari EMAIL logo , Analía V. Freire , María E. Escobar , María G. Ballerini , María G. Ropelato , Ignacio Bergadá and Mirta G. Gryngarten



Puberty is associated with a physiological decline in insulin sensitivity (IS). Overweight (OW) and obesity (OB) are common among girls with central precocious puberty (CPP). CPP is considered a risk factor for metabolic diseases. The aim of this study was to assess surrogate measures of IS, body mass index (BMI) and other metabolic parameters in CPP girls at diagnosis and during treatment with gonadotropin-releasing hormone analogues (GnRHa).


We present a prospective longitudinal study of CPP girls. The standard oral glucose tolerance test, homeostatic model assessment of insulin resistance (HOMA-IR), whole-body IS index (ISI) and fasting lipid profiles were evaluated at diagnosis, and at 6 and 12 months of treatment.


Nineteen CPP girls were included; 17 were evaluable. At baseline, seven patients had normal weight (NW), five were OW and five were OB. During GnRHa treatment no significant changes were observed in BMI, HOMA-IR or ISI when considering the whole group. Whereas, when we analyzed patients according to BMI status, in NW patients, BMI increased significantly with no changes in HOMA-IR or ISI along treatment. In the OW/OB group, no significant differences were observed in BMI, HOMA-IR or ISI.


Girls with CPP showed a high frequency of OW/OB and a high prevalence of IR. GnRHa did not affect BMI, IS or the lipid profile when considering the whole cohort of patients. However, there was an increase in BMI in NW girls but not in OW/OB patients.

Corresponding author: Andrea J. Arcari, MD, Centro de Investigaciones Endocrinológicas “Dr. César Bergadá” (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Dr. Ricardo Gutiérrez, Gallo 1330, C1425EFD Buenos Aires, Argentina, Tel: +5411-4963-5931 ext 127, Fax: +5411-4963-5930, E-mail:

  1. Acknowledgments

  2. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  3. Research funding: This research was partially sponsored by the “Consejo de Investigación en Salud, Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires (CIS-GCBA)” to M.G.G.

  4. Employment or leadership: M.G.G., M.G.B., I.B. and M.G.R. are research members at the “Carrera de Investigador en Salud, Ministerio de Salud, Gobierno de la Ciudad Autónoma de Buenos Aires”.

  5. Honorarium: None declared.

  6. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Parent AS, Franssen D, Fudvoye J, Gérard A, Bourguignon JP. Developmental variations in environmental influences including endocrine disruptors on pubertal timing and neuroendocrine control: revision of human observations and mechanistic insight from rodents. Front Neuroendocrinol 2015;38:12–36.10.1016/j.yfrne.2014.12.004Search in Google Scholar PubMed

2. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001;50:2444–50.10.2337/diabetes.50.11.2444Search in Google Scholar PubMed

3. Palmert MR, Mansfield MJ, Crowley Jr WF, Crigler Jr JF, Crawford JD, et al. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480–8.Search in Google Scholar

4. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626–34.10.1111/j.1365-2265.2004.02146.xSearch in Google Scholar PubMed

5. Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, et al. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463–4.10.1530/eje.1.01975Search in Google Scholar PubMed

6. Tascilar ME, Bilir P, Akinci A, Kose K, Akcora D, et al. The effect of gonadotropin-releasing hormone analog treatment (leuprolide) on body fat distribution in idiopathic central precocious puberty. Turk J Pediatr 2011;53:27–33.Search in Google Scholar

7. Arcari AJ, Gryngarten MG, Freire AV, Ballerini MG, Ropelato MG, et al. Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues. J Pediatr Endocrinol 2016;15:1–7.10.1186/s13633-016-0033-7Search in Google Scholar PubMed PubMed Central

8. Garn SM, LaVelle M, Rosenberg KR, Hawthorne VM. Maturational timing as a factor in female fatness and obesity. Am J Clin Nutr 1986;43:879–83.10.1093/ajcn/43.6.879Search in Google Scholar PubMed

9. Lakshman R, Forouhi N, Luben R, Bingham S, Khaw K, et al. Association between age at menarche and risk of diabetes in adults: results from the EPIC-Norfolk cohort study. Diabetology 2008;51:781–6.10.1007/s00125-008-0948-5Search in Google Scholar PubMed

10. Lakshman R, Forouhi NG, Sharp SJ, Luben R, Bingham SA, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 2009;94:4953–60.10.1210/jc.2009-1789Search in Google Scholar PubMed

11. Golub MS, Collman GW, Foster PM, Kimmel CA, Rajpert-De Meyts E, et al. Public health implications of altered puberty timing. Pediatrics 2008;121(Suppl 3):S218–30.10.1542/peds.2007-1813GSearch in Google Scholar PubMed

12. Remsberg KE, Demerath EW, Schubert CM, Chumlea WC, Sun SS, et al. Early menarche and the development of cardiovascular disease risk factors in adolescent girls: the Fels Longitudinal Study. J Clin Endocrinol Metab 2005;90:2718–2724.10.1210/jc.2004-1991Search in Google Scholar PubMed

13. Raitakari OT, Porkka KV, Rönnemaa T, Knip M, Uhari M, et al. The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The Cardiovascular Risk in Young Finns Study. Diabetologia 1995;38:1042–1050.10.1007/BF00402173Search in Google Scholar PubMed

14. Boot AM, De Muinck K-SS, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 1998;83:370–3.Search in Google Scholar

15. Feuillan P, Jones J, Barnes K, Oerter-Klein K, Cutler Jr G. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44–9.10.1210/jcem.84.1.5409Search in Google Scholar PubMed

16. Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, et al. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab 2000;13(Suppl 1):791–4.10.1515/JPEM.2000.13.S1.791Search in Google Scholar

17. Chiocca E, Dati E, Baroncelli GI, Mora S, Parrini D, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology 2009;89:441–7. DOI: 10.1159/000197862. Epub 2009 Jan 29.10.1159/000197862Search in Google Scholar PubMed

18. Anık A, Çatlı G, Abacı A, Böber E. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab 2015;19:267–71.10.4103/2230-8210.131770Search in Google Scholar PubMed PubMed Central

19. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583–90.Search in Google Scholar

20. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002;87:2090–4.10.1210/jcem.87.5.8481Search in Google Scholar PubMed

21. Glab E, Barg E, Wikiera B, Grabowski M, Noczyńska A. Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab 2009;15:7–11.Search in Google Scholar

22. Ko JH, Lee HS, Lim JS, Kim SM, Hwang JS. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist. Horm Res Paediatr 2011;75:174–9.10.1159/000320039Search in Google Scholar PubMed

23. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506–12.10.1210/jcem.87.2.8202Search in Google Scholar PubMed

24. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533–7.10.1530/eje.0.1500533Search in Google Scholar PubMed

25. Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011;27:524–8.10.3109/09513590.2010.507289Search in Google Scholar PubMed

26. Sorensen K, Mouritsen A, Mogensen SS, Aksglaede L, Juul A. IS and lipid profiles in girls with central precocious puberty before and during gonadal suppression. J Clin Endocrinol Metab 2010;95:3736–3744.10.1210/jc.2010-0731Search in Google Scholar PubMed

27. Colmenares A, Gunczler P, Lanes R. Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. Int J Pediatr Endocrinol 2014;2014:5. DOI: 10.1186/1687-9856-2014–5.10.1186/1687-9856-2014–5Search in Google Scholar

28. Park J, Kim JH. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab 2017;22:27–35.10.6065/apem.2017.22.1.27Search in Google Scholar PubMed PubMed Central

29. Freire AV, Gryngarten MG, Ballerini MG, Arcari AJ, Escobar ME, et al. Assessment of estradiol response after depot triptorelin administration in girls with central precocious puberty. Horm Res Paediatr 2016;85:58–64.10.1159/000442523Search in Google Scholar PubMed

30. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.10.1136/adc.44.235.291Search in Google Scholar PubMed PubMed Central

31. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Palo Alto, CA: Stanford University Press; 1959.10.1097/00000441-195909000-00030Search in Google Scholar

32. Cole TJ, Bellizi MC, Fiegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J 2000;320:1240–3.10.1136/bmj.320.7244.1240Search in Google Scholar PubMed PubMed Central

33. Browning L, Hsieh S, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev 2010; 23:247–69.10.1017/S0954422410000144Search in Google Scholar PubMed

34. Ballerini MG, Bergadá I, Rodríguez ME, Keselman A, Bengolea VS, et al. Insulin level and IS indices among healthy children and adolescents. Arch Argent Pediatr 2016;114:329–36.Search in Google Scholar

35. Matsuda M, DeFronzo RA. IS indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70.10.2337/diacare.22.9.1462Search in Google Scholar PubMed

36. Arancibia C, Galgani J, Valderas JP, Morales M, Santos JL, et al. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance Rev Med Chile 2014;142:1106–12.10.4067/S0034-98872014000900003Search in Google Scholar PubMed

37. Araujo MB, Casavalle P, Tonietti M, Ozuna B, Andres ME, et al. Comité de nutrición: Consensus on management of dyslipidemia in pediatrics. Arch Argent Pediatr 2015;13:177–86.Search in Google Scholar

38. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, et al. Use of the oral glucose tolerance test to assess insulin release and IS. Diabetes Care 2000;23:295–301.10.2337/diacare.23.3.295Search in Google Scholar PubMed

Received: 2018-07-29
Accepted: 2018-12-16
Published Online: 2019-01-30
Published in Print: 2019-02-25

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 31.3.2023 from
Scroll to top button